BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8787054)

  • 1. Serum (circulating) tumor markers for breast cancer.
    Hayes DF
    Recent Results Cancer Res; 1996; 140():101-13. PubMed ID: 8787054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor markers for breast cancer.
    Hayes DF
    Ann Oncol; 1993 Dec; 4(10):807-19. PubMed ID: 8117599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor markers for breast cancer. Current utilities and future prospects.
    Hayes DF
    Hematol Oncol Clin North Am; 1994 Jun; 8(3):485-506. PubMed ID: 8707769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
    Pectasides D; Pavlidis N; Gogou L; Antoniou F; Nicolaides C; Tsikalakis D
    Am J Clin Oncol; 1996 Oct; 19(5):459-64. PubMed ID: 8823487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
    Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
    J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEA, TPA and CA 15.3 in tissue and serum of breast cancer patients.
    Saccani Jotti G; Grassi C; Fontanesi M; Becchi G; Gion M
    Int J Biol Markers; 1992; 7(4):265-6. PubMed ID: 1491185
    [No Abstract]   [Full Text] [Related]  

  • 9. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
    Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
    East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
    Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
    Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts.
    Nicolini A; Carpi A; Ferrari P; Anselmi L
    Int J Biol Markers; 1997; 12(4):181-6. PubMed ID: 9582609
    [No Abstract]   [Full Text] [Related]  

  • 15. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
    van Dalen A
    Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA 549 and SP2: new tumor markers in breast cancer.
    Torres M; Jiménez-Heffernan A; García A; Valverde A; Mateo A
    Int J Biol Markers; 1990; 5(2):97-8. PubMed ID: 2283484
    [No Abstract]   [Full Text] [Related]  

  • 17. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Winkel P; Mouridsen HT; Dombernowsky P
    Ann Oncol; 1993 Dec; 4(10):861-9. PubMed ID: 8117606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
    Barrenetxea G; Schneider J; Llorente MF
    Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
    [No Abstract]   [Full Text] [Related]  

  • 19. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.
    Devine PL; Duroux MA; Quin RJ; McGuckin MA; Joy GJ; Ward BG; Pollard CW
    Breast Cancer Res Treat; 1995 Jun; 34(3):245-51. PubMed ID: 7579489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer.
    Nicolini A; Carpi A; Ferrari P; Anselmi L; Spinelli C; Conte M; Miccoli P
    Br J Cancer; 2000 Dec; 83(11):1412-7. PubMed ID: 11076646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.